Inclusion Criteria:

- Patients will be required to have clear cell renal cell carcinoma with less than 50%
of any other histology (papillary or chromophobe or oncocytic). There must be
histologic confirmation by the treating center of either the primary or a metastatic
lesion

- Patients must have experienced disease progression by RECIST criteria while on
sorafenib or sunitinib

- Patients must be off of sorafenib or sunitinib for >= 2 weeks prior to initiation of
perifosine and <= 3 months prior to enrollment

- Patients may have had sorafenib or sunitinib in the adjuvant setting as long as they
have experienced disease recurrence while on therapy

- Patients must have measurable disease that is not curable by standard radiation
therapy or surgery

- Age >= 18 years

- ECOG performance status 0 or 1

- - Patients must have the ability to understand and willingness to sign a written
informed consent document

Exclusion Criteria:

- History or clinical evidence of CNS disease, including primary brain tumor, seizures
not controlled with standard medical therapy, any brain metastasis, or history of
stroke

- Other than sorafenib or sunitinib, patients may have only had prior immunotherapy for
stage IV disease

- Patients may have had prior sorafenib OR sunitinib and cannot have been treated with
both TKIs

- Patients who have stopped sorafenib or sunitinib due to toxicity but have only
progressed off therapy will not be allowed

- Patients may have had prior anti-angiogenic such as bevacizumab only if given in
combination with either sorafenib or sunitinib

- Prior Thalidomide or IFNα are allowed for adjuvant therapy or stage IV disease

- Patients may not have had prior mTOR inhibitors (CCI-779, RAD001)